Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on Non-targeted treatment Has Begun Research Led by Dr. Gregory Vidal Evidences Identifies Inequities by…